Maintenance Notice (2:00 - 4:00 AM July 12, 2026 UTC): The website is scheduled for maintenance. The website will be available, but some functions may experience errors. We appreciate your patience and understanding.
Product Document Searching Made Easy by 2D Code! | TCI Life Science News July 2026 | [Product Highlights] Mitochondrial Membrane Potential... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
CAS RN: 132539-06-1 | Product Number: O0393
Olanzapine
Purity: >98.0%(GC)(T)
- 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 1G |
$89.00
|
22 | 10 | Contact Us | |
| 5G |
$306.00
|
≥60 | 5 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | O0393 |
Purity / Analysis Method
|
>98.0%(GC)(T) |
| Molecular Formula / Molecular Weight | C__1__7H__2__0N__4S = 312.44 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 132539-06-1 |
| Reaxys Registry Number | 7655141 |
| PubChem Substance ID | 160871343 |
| Merck Index (14) | 6822 |
| MDL Number | MFCD00866702 |
| Appearance | Light yellow to Amber to Dark green powder to crystal |
| Purity(GC) | min. 98.0 % |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting Point | 194 °C(dec.) |
| Solubility in water | Insoluble |
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H301 : Toxic if swallowed. H315 : Causes skin irritation. H319 : Causes serious eye irritation. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
| RTECS# | XJ9007750 |
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | III |
| H.S.code* | 2934.99-000 |
References
- Atypical antipsychotics induce human osteoblasts apoptosis via Wnt/β-catenin signaling
- Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients
Recently, it is reported that the use of olanzapine combined with a 5-HT3 receptor antagonist, a neurokinin1 (NK1) receptor antagonist and dexamethasone [D1961] has improved the control of acute chemotherapy-induced nausea and vomiting. (The product is for research purpose only.)
References
- Radioreceptor binding profile of the atypical antipsychotic olanzapine
- Binding of antipsychotic drugs to human brain receptors - focus on newer generation compounds
- 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release
- Olanzapine: An updated review of its use in the management of schizophrenia
- Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhea
- Pharmacokinetics and tissue distribution of olanzapine in rats
- Development of a stability-indicating HPLC method for simultaneous determination of olanzapine and fluoxetine in combined dosage forms
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.